Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

NCT00102050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Intermittent Claudication
Peripheral Vascular Disease

Interventions

DRUG: NM-702 (phosphodiesterase inhibitor)

Sponsor

Nissan Chemical Industries